Live feed13:02:00·699dPRReleasevia QuantisnowAffimed Provides Follow-up Data of AFM24 plus Atezolizumab Showing Durable Responses in Heavily Pretreated NSCLC EGFR Wild-type Patients and Positive Initial Data from the NSCLC EGFR Mutant CohortByQuantisnow·Wall Street's wire, on your screen.AFMD· Affimed N.V.Health Care
